tag myeloma-patients-europe 
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Of these patients, seven have been treated at the recommended phase II dose (RP2D) and regimen.
pharmaphorum
MARCH 27, 2022
Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. The post CHMP backs J&J’s myeloma CAR-T therapy Carvykti appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 17, 2020
Suri explains that in the case of cancer immunotherapy, the conventional “carpet bombing” approaches of broadly activating the immune system — or in cases of autoimmunity, broadly immunosuppressing it — has implications for patient safety. There is great unmet need in head and neck cancer as patients don’t have a lot of treatment options.
Drug Discovery World
NOVEMBER 9, 2023
Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. These include: Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, on: ‘AI-based target and antibody discovery from patient tumour profiles’.
The Pharma Data
MAY 4, 2021
Each of these accomplishments further demonstrates our commitment to Pfizer’s purpose: Breakthroughs that change patients’ lives.”. I remain confident in Pfizer’s ability to continue to deliver on our commitments to our patients and shareholders in 2021 and beyond.”. This will make 2021 the 12th year in a row with a dividend increase.
Expert insights. Personalized for you.
52 
Let's personalize your content